TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
Several hematologic disorders are associated with anemia that can be linked to ineffective erythropoiesis. This occurs when the marrow cannot maintain adequate red blood cell production or produces defective or immature cells that are incapable of proper functioning. Myelodysplastic syndromes (MDS), myeloproliferative neoplasms and beta thalassemia are examples of disorders often associated with moderate to severe anemia. Few treatment options are available for inherited and acquired disorders of erythropoiesis, and despite significant research gains many uncertainties and clinical challenges persist in regard to the management of related anemia. Thus it is imperative that the oncology community have access to up-to-date medical education programs designed to comprehensively address current therapeutic approaches and promising research that can facilitate effective clinical decision-making.

To bridge the gap between research and patient care, this program features one-on-one discussions with leading hematology-oncology investigators. Upon completion of this CME activity, medical oncologists and hematologists should be able to formulate an up-to-date and more complete approach to the care of patients with anemia associated with hematologic disorders.

LEARNING OBJECTIVES
• Understand the causes and consequences of blood disorder-associated anemia, and use this information to refine disease management and supportive care of patients.
• Describe the biologic rationale for and mechanism of action of erythroid maturation agents (EMAs) in the treatment of anemia secondary to select hematologic disorders, including MDS, beta thalassemia and myelofibrosis.
• Appraise emerging clinical data with the EMA luspatercept in preparation for its potential availability for the management of beta thalassemia and/or low-risk MDS.
• Recognize the importance of screening for iron overload in transfusion-dependent patients, and develop a systematic approach for initiating and delivering iron chelation therapy.
• Analyze the biologic basis for and early research data with gene-based therapies for beta thalassemia.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/Anemia19/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/Anemia19.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Rami Komrokji, MD
Senior Member
Section Head, Leukemia and MDS
Vice Chair, Department of Malignant Hematology
H Lee Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, Florida

Consulting Agreements: Celgene Corporation, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Novartis; Speakers Bureau: Jazz Pharmaceuticals Inc, Novartis.

Maria-Domenica Cappellini, MD
Professor of Internal Medicine
University of Milan
Fondazione IRCCS Ca’ Granda Ospedale Policlinico
Milan, Italy

Advisory Committee: Celgene Corporation, Genzyme Corporation, Novartis, Sanofi Genzyme, Vifor Pharma.


RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Celgene Corporation.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: July 2019
Expiration date: July 2020
A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment of patients affected by transfusion dependent beta-thalassemia. NCT02453477

A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus epoetin alpha for the treatment of anemia due to IPSS-R very low, low or intermediate risk due to myelodysplastic syndrome (MDS) ESA in native subjects who require red blood cell transfusions. NCT03682536

Angelucci E et al. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): Outcomes from the randomized, double-blind Telesto study. Proc ASH 2018;Abstract 234.


Cappellini M et al. The BELIEVE trial: Results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept in adult beta-thalassemia patients who require regular red blood cell (RBC) transfusions. Proc ASH 2018;Abstract 163.


Fenaux P et al. The MEDALIST trial: Results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions. Proc ASH 2018;Abstract 1.


